Back to search
FDAFDA · Food and drugs·Recall number Z-1996-2026

iLet Bionic Pancreas, REF: BB1001

Published May 6, 2026 · Recall initiated: March 12, 2026

Summary

FDA records medical device Class II recall Z-1996-2026, published May 6, 2026 and initiated March 12, 2026. Recalling firm: Beta Bionics, Inc.; Status: Ongoing; Reported quantity: 1,080; Lot: Software versions 1.4.3, and 1.4.2. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

insulin pump software versions 1.4.2, and 1.4.3 issue with Dexcom Continuous Glucose Monitoring (CGM) G7 sensor may result in delayed CGM reading then switch to non-CGM dosing, leading to only basal/requested meal doses provided, no correction doses/insulin reductions/suspensions for high/low glucose unless blood glucose entered for sensor life or replacement. Potential health risks to users include severe hyperglycemia with and without DKA and severe hypoglycemia.

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Beta Bionics, Inc.
Distributor
US Nationwide distribution in the states of TX, PA, AL, MI, OH, FL, TN, GA.
Lot
Software versions 1.4.3, and 1.4.2
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was iLet Bionic Pancreas, REF: BB1001 recalled?

Yes. FDA published recall Z-1996-2026 on May 6, 2026. Reported hazard: insulin pump software versions 1.4.2, and 1.4.3 issue with Dexcom Continuous Glucose Monitoring (CGM) G7 sensor may result in delayed CGM reading then switch to non-CGM dosing, leading to only basal/requested meal doses provided, no correction doses/insulin reductions/suspensions for high/low glucose unless blood glucose entered for sensor life or replacement. Potential health risks to users include severe hyperglycemia with and without DKA and severe hypoglycemia.

What should I do if I have this product?

Voluntary: Firm initiated